What is the Medico Remedies PE ratio today?
Medico Remedies' PE ratio is 11.4 at the 29 October 2026 close (₹18.98 a share): a market capitalisation of ₹158 crore divided by consolidated net profit of ₹13.8 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹13.1 crore) it is 12.0.
What is the Medico Remedies debt to equity ratio?
Medico Remedies' debt-to-equity ratio was 0.25 on 31 March 2026: borrowings of ₹18.8 crore against total equity of ₹75.5 crore. A year earlier, on 31 March 2025, it was 0.24.
What is the Medico Remedies net worth?
Medico Remedies' net worth — shareholders' equity in its consolidated balance sheet — was ₹75.5 crore on 31 March 2026, up 21.2% from ₹62.3 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹158 crore at the 29 October 2026 close.
What is the Medico Remedies PB ratio (price to book value)?
Medico Remedies' price-to-book (PB) ratio is 2.09 at the 29 October 2026 close: a market capitalisation of ₹158 crore divided by shareholders' equity (book value) of ₹75.5 crore on 31 March 2026. That is a book value of ₹9.10 per share against a share price of ₹18.98.
What is the Medico Remedies ROE and ROCE?
In FY26, Medico Remedies' return on equity (ROE) was 19.0% and its return on capital employed (ROCE) was 20.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 17.6% and ROCE 20.6%.
What is the Medico Remedies book value per share?
Medico Remedies' book value per share was ₹9.10 on 31 March 2026: shareholders' equity of ₹75.5 crore divided by the 8.3 crore shares in issue, up 21.2% from ₹7.51 a year earlier. The share price at the 29 October 2026 close was ₹18.98.
What is the Medico Remedies market cap?
Medico Remedies' market capitalisation was ₹158 crore at the 29 October 2026 close: 8.3 crore shares at ₹18.98 each.
Is Medico Remedies debt free?
No. Medico Remedies had borrowings of ₹18.8 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.25. Its cash and current investments were ₹3.8 crore, so its net debt was ₹15.1 crore.
What is the Medico Remedies EPS?
Medico Remedies' basic earnings per share (EPS) were ₹1.58 in FY26, against ₹1.22 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹1.67.
What is the Medico Remedies promoter holding?
Promoters held 61.38% of Medico Remedies on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Medico Remedies free cash flow?
In FY26, Medico Remedies generated ₹5.9 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹5.9 crore. In FY25 it was ₹4.9 crore.
When are the Medico Remedies next results?
Medico Remedies has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
What is the Medico Remedies shareholding pattern?
On 30 September 2026, Medico Remedies' shares were held by promoters 61.38%, foreign portfolio investors (FII/FPI) 0.60%, domestic institutions (DII) 0.00% (including mutual funds at 0.00%) and retail and other non-institutional investors 38.02%. Over the year, FII holding was up 0.30 percentage points from 0.30% and DII holding was down 0.01 percentage points from 0.01%.
What are the Medico Remedies latest quarterly results?
Medico Remedies' latest results are for Q1 FY27 (April–June 2026), filed on 13 August 2026: consolidated net profit ₹2.5 crore, up 38.5% from ₹1.8 crore in Q1 FY26; revenue from operations ₹69.4 crore, up 81.4% year on year.
How does the Medico Remedies PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Medico Remedies' PE ratio is 12.0, the lowest of the four: Medicamen Biotech 37.6, HALEOS LABS 25.0 and Aarey Drugs & Pharmaceuticals 79.5, a peer average of 47.3. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What is the Medico Remedies revenue and profit in FY26?
In FY26 (April 2025–March 2026), Medico Remedies' consolidated net profit was ₹13.1 crore, up 29.9% from ₹10.1 crore in FY25, on revenue from operations of ₹206 crore (up 36.7%). Over three years, from FY23, net profit was up 81.1%.
How does Medico Remedies compare with its peers?
On FY26 consolidated figures, against Medicamen Biotech, HALEOS LABS and Aarey Drugs & Pharmaceuticals: Medico Remedies' operating margin of 6.8% is the second highest of the four (Medicamen Biotech 6.3%, HALEOS LABS 8.8%, Aarey Drugs & Pharmaceuticals 0.9%; peer average 5.3%); its return on equity of 19.0% is the highest of the four (Medicamen Biotech 4.0%, HALEOS LABS 8.4%, Aarey Drugs & Pharmaceuticals 2.8%; peer average 5.0%); its revenue growth over three years of 13.7% a year is the second highest of the four (Medicamen Biotech 12.0% a year, HALEOS LABS 1.9% a year, Aarey Drugs & Pharmaceuticals 96.3% a year; peer average 36.7% a year).
Medico Remedies vs Medicamen Biotech: how do they compare?
In FY26, Medico Remedies earned net profit of ₹13.1 crore on revenue of ₹206 crore, against ₹9.6 crore on ₹198 crore for Medicamen Biotech. Medico Remedies' operating margin was 6.8% (Medicamen Biotech 6.3%) and its return on equity 19.0% (Medicamen Biotech 4.0%). At the 29 October 2026 close, Medico Remedies' market capitalisation was ₹158 crore against ₹362 crore for Medicamen Biotech, and its PE ratio on FY26 profit 12.0 against 37.6.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
